LANGUAGE
KOREANENGLISH
LOCATION
  • COMPANY
  • R&D
    • R&D Institute
    • GMP Center
    • Clinical Development Status
    • Publications
  • PRODUCTS
    • 1st Generation
      • Overview
      • CARTISTEM®
      • PNEUMOSTEM®
    • 2nd Generation
      • Overview
      • SMUP-IA-01
      • SMUP-IV-01
    • R&D Inquiries
  • BUSINESS
    • CDMO
      • Quality System
      • CDMO Service
      • Quality Control
      • Global CDMO
      • CDMO Inquiries
    • CELLTREE Cord Blood Bank
    • MOVITA Nutritional Supplements
  • IR
    • Stock Information
    • Disclosure
    • Financial Information
    • IR Inquiries
  • PR
    • MEDIPOST on Media
    • Corporate Brochure
  • CONTACT US
    • Customer Center
    • R&D Inquiries
    • CDMO Inquiries
    • IR Inquiries

MEDIPOST gets patent in US

2013/06/13
STEM CELL THERAPEUTIC

MEDIPOST announced that it got a patent registered in the United States for treating cancer using stem cells.

The biotechnology company said that it received the patent from the United States Patents and Trademark Office for the technology it developed, which treats patients by combining cancer-repressing genes with cord blood stem cells. The company also had patents registered in a number of European countries in March for this technology.

The company explained that it can be used to track diverse cancers including those in the brain, breasts, and rectal passage, and expressed hope that it can also be applied in the development of a cure for Alzheimer’s disease.

VIEW LIST

Related News

news 1
MEDIPOST Recruits Local Experts to U.S. Subsidiary, Accelera…
2024/12/06
cartistem package
MEDIPOST Completes Administration for Phase 3 Clinical Trial…
2024/11/22

Latest News

news 1
MEDIPOST Recruits Local Experts to U.S. Subsidiary, Accelera…
2024/12/06
cartistem package
MEDIPOST Completes Administration for Phase 3 Clinical Trial…
2024/11/22
news 241022
MEDIPOST Affiliate OmniaBio Hosts Opening Ceremony for New C…
2024/10/21
news 241015
MEDIPOST Discusses CARTISTEM® Partnerships and Licensing Opp…
2024/10/14
news 1
MEDIPOST Recruits Local Experts to U.S. Subsidiary, Accelera…
2024/12/06
cartistem package
MEDIPOST Completes Administration for Phase 3 Clinical Trial…
2024/11/22
news 241022
MEDIPOST Affiliate OmniaBio Hosts Opening Ceremony for New C…
2024/10/21
news 241015
MEDIPOST Discusses CARTISTEM® Partnerships and Licensing Opp…
2024/10/14

Contacts

21, Daewangpangyo-ro 644, Bundang-gu, Seongnam-si, Gyeonggi-do, Korea MEDIPOST Co., Ltd.
TEL : 82-2-3465-6677

Latest News

MEDIPOST Recruits Local Experts to U.S.…2024.12.06
MEDIPOST Completes Administration for Ph…2024.11.22
MEDIPOST Affiliate OmniaBio Hosts Openin…2024.10.21
MEDIPOST Discusses CARTISTEM® Partnershi…2024.10.14
MEDIPOST’s CARTISTEM® Reaches Milestone…2024.06.24

Family Site

· CELLTREE Cord Blood Bank
· MOVITA Nutritional Supplements

· LOCATION
· PRIVACY POLICY

©Copyright – The Future of Biotechnology, MEDIPOST